Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
DXF | Well someone had to do it | 03/04/19 | 229 | 40K | |||
|
|||||||
DXF | Ann: Removal from Official List | 11/08/18 | 12 | 4.5K | |||
|
|||||||
DXF | Ann: Market Update | 14/05/18 | 9 | 3.5K | |||
|
|||||||
DXF | Ann: S&P DJ Indices Announces March Quarterly Rebalance | 09/03/18 | 0 | 458 | |||
|
|||||||
DXF | Ann: S&P DJ Indices Announces March Quarterly Rebalance | 09/03/18 | 0 | 323 | |||
|
|||||||
DXF | Ann: Appendix 4C | 12/02/18 | 0 | 689 | |||
|
|||||||
DXF | Ann: Release of Securities from Voluntary Escrow | 09/02/18 | 0 | 531 | |||
|
|||||||
DXF | Ann: Appendix 4C | 31/10/17 | 0 | 446 | |||
|
See All Discussions